← Leaderboards
Behnam Badie
Beckman Research Institute/City Of Hope
$11,237,051
Attributed
$15,256,887
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,302,521 · 12
FDA$600,000 · 1
By mechanism
R01$13,352,423 · 6
U19$4,951,366 · 3
R21$1,244,550 · 3
P30$354,182 · 1
Top collaborators
- Christine Brown14 shared
- Jana Portnow5 shared
- Jacob M Berlin2 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Ann Marie Schmidt$32,042,569
- Christine Brown$5,264,024
- Jana Portnow$3,811,944
- Jianhua Yu$11,234,533
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTumorImmunotherapyPathway InteractionsGlioblastomaClinical TrialsImmuneGliomaInnovationNeoplastic CellResponseTumor MicroenvironmentMediatingPreclinical StudyDesignBrain NeoplasmsCytokineMolecularPhase I Clinical TrialsCombined Modality TherapySuccessInflammatoryLigandsMalignant Glioma
Grant awards (43)
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability$925,385
U19 · FY2025 · CA
Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation$571,835
R01 · FY2025 · NS · contact PI
Novel Neurosurgical Device for Evacuation of Intracerebral Hematoma$439,239
R01 · FY2025 · NS · contact PI
An engineered oncolytic herpes virus expressing a full-length α-CD47 mAb for the treatment of GBM$176,146
U19 · FY2025 · CA · contact PI
Tasquinimod as an adjunct to immunotherapies administered peri-operatively$129,586
U19 · FY2025 · CA · contact PI
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability$882,648
U19 · FY2024 · CA
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma$809,915
R01 · FY2024 · CA
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma$711,759
R01 · FY2024 · CA
Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation$570,541
R01 · FY2024 · NS · contact PI
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability$917,677
U19 · FY2023 · CA
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma$734,238
R01 · FY2023 · CA
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma$469,554
R01 · FY2023 · CA
Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation$440,000
R01 · FY2023 · NS · contact PI
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability$920,861
U19 · FY2022 · CA
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma$734,238
R01 · FY2022 · CA
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma$1
R01 · FY2022 · CA
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability$999,063
U19 · FY2021 · CA
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma$749,221
R01 · FY2021 · CA
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma$665,841
R01 · FY2021 · CA
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors$410,877
R01 · FY2021 · CA · contact PI
GMP Manufacturing Core$173,519
P30 · FY2021 · CA · contact PI
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma$768,221
R01 · FY2020 · CA
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma$665,839
R01 · FY2020 · CA
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors$407,551
R01 · FY2020 · CA · contact PI
GMP Manufacturing Core$180,663
P30 · FY2020 · CA · contact PI
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma$665,839
R01 · FY2019 · CA
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors$413,174
R01 · FY2019 · CA · contact PI
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors$410,877
R01 · FY2018 · CA · contact PI
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors$410,877
R01 · FY2017 · CA · contact PI
Phase 1 Study of Cellular Immunotherapy Using Optimized IL13Ra2 Specific CAR T cells for the Treatment of Malignant Glioma$200,000
R01 · FY2017 · FD · contact PI
Phase 1 Study of Cellular Immunotherapy Using Optimized IL13Ra2 Specific CAR T cells for the Treatment of Malignant Glioma$200,000
R01 · FY2016 · FD · contact PI
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumor$348,600
R01 · FY2015 · CA · contact PI
Novel Cell Delivery Method for Brain Tumor Therapy$230,375
R21 · FY2015 · CA · contact PI
Phase 1 Study of Cellular Immunotherapy Using Optimized IL13Ra2 Specific CAR T cells for the Treatment of Malignant Glioma$200,000
R01 · FY2015 · FD · contact PI
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumor$338,142
R01 · FY2014 · CA · contact PI
Dynamic Magnetic Targeting of Activated Brain Macrophages for Glioma Therapy$195,117
R21 · FY2014 · NS · contact PI
Novel Cell Delivery Method for Brain Tumor Therapy$183,969
R21 · FY2014 · CA · contact PI
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumor$327,684
R01 · FY2013 · CA · contact PI
Dynamic Magnetic Targeting of Activated Brain Macrophages for Glioma Therapy$269,889
R21 · FY2013 · NS · contact PI
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumor$348,600
R01 · FY2012 · CA · contact PI
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumor$339,760
R01 · FY2011 · CA · contact PI
Application of Carbon Nanotubes for Macrophage Activation in Brain Tumor Models$182,600
R21 · FY2010 · CA · contact PI
Application of Carbon Nanotubes for Macrophage Activation in Brain Tumor Models$182,600
R21 · FY2009 · CA · contact PI